Skip to content
LATEST
US Politics

HHS Draft Policy Proposes Regulatory Framework for Compounding Six Unapproved Peptides

HHS has introduced a draft policy allowing licensed pharmacies to compound six unapproved peptides to reduce reliance on unregulated gray market sources.

HHS Draft Policy Proposes Regulatory Framework for Compounding Six Unapproved Peptides

The Department of Health and Human Services has released a draft interim policy to permit the compounding of six specific peptides by licensed pharmacies and physicians. The substances included are BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon. Under this policy, the agency intends to exercise enforcement discretion, allowing these substances to be prepared for individual patients despite lacking formal FDA approval.

This regulatory shift aims to mitigate risks associated with the current unregulated gray market for these substances. By transitioning access to state-licensed facilities, the policy mandates patient-specific prescriptions, ingredient traceability, and quality testing. The agency maintains that this framework does not constitute an endorsement of the safety or clinical efficacy of these peptides.

The draft policy is subject to a 14-day public comment period before a final determination is issued. While the move provides a legal pathway for compounding, the substances remain outside the standard FDA review process for safety and effectiveness. The policy serves as a temporary measure pending a final rule regarding the inclusion of these peptides on the list of approved ingredients for customized medications.

More stories

Latest news